Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reactions to infliximab.
- At: 2006 FIP Congress in Salvadore (Brazil)
- Type: Poster
- By: AUGUSTSSON, Jenny (Apoteket AB, Stockholm, Sweden)
- Co-author(s): Ernestam, Sofia (Karolinska Institute, STOCKHOLM, Sweden)
Eksborg, Staffan (Karolinska Institute, STOCKHOLM, Sweden)
Van Vollenhoven, Ronald (Karolinska Institute, STOCKHOLM, Sweden)
Infusion reactions are a well-described complication of infliximab (Remicade) therapy and represent the cause of appr. 15% of the discontinuations of this treatment. The aim of this study was to investigate the role of glucocorticoids and possible predictors of infusion reactions, thus improving the patient safety.
.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.